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TWICE-WEEKLY ABLC PROPHYLAXIS FOR PATIENTS AT HIGH RISK OF
INVASIVE FUNGAL INFECTION AFTER ALLOGENEIC STEM CELL TRANS-
PLANTATION
Jansen, J., Akard, L.P., Wack, M.F., Thompson, J.M., Dugan, M.J.,
Leslie, J.K., Mattison, R.H. Indiana Blood and Marrow Transplanta-
tion, Indianapolis, IN.
Invasive fungal infections (IFIs) are increasing after allogeneic
stem cell transplantation (aSCT). Known prognostic factors for IFI
include mismatched donors, severe GvHD, CMV infection, and
the use of steroids. Our group treated all patients during their
initial neutropenic episode with oral ﬂuconazole or itraconazole
(200–400 mg/day). Starting on day 30, patients who received
prednisone  30 mg/day were switched to intravenous amphoter-
icin-B lipid complex (ABLC; Abelcet) at a dosage of 4 mg/kg twice
a week. Patients who received lower steroid doses continued their
ﬂuconazole/itraconazole until at least day 100 after SCT. Be-
tween 1999 and 2002, a total of 100 patients were enrolled, includ-
ing 24 patients with unrelated donors and 11 patients with partially
mismatched related donors. Good-risk patients were a minority
(27%), whereas 32% had overt relapse and/or refractory disease.
Preparative regimens contained TBI (45%), busulfan/cyclophos-
phamide (35%), or ﬂudarabine (20%). BM and PBSC were the
source of stem cells in 43% and 57% of patients, respectively.
Prophylaxis of aGvHD was based on cyclosporine but included
steroids in 27%, in vivo T-cell depletion in 25%, and in vitro
T-cell depletion in 15% of patients. Out of 37 patients who did not
receive ABLC prophylaxis, 2 developed IFI beyond day 30 (1
from Aspergillus on day 36, 1 from Candida on day 63). A total
of 63 patients did receive prophylactic ABLC for a median of 52
days (range, 1 to 289 days). Six of the patients at such high risk of
IFI that they were assigned to ABLC prophylaxis still developed
IFI (3 from Aspergillus at days 45, 65, and 255 and 3 from
Candida at days70,72, and210). An additional 2 patients had
probable, but undocumented, IFI. Univariate analysis of all pa-
tients with IFI showed that factors increasing the risk of IFI were
BM as the stem cell source, MUD or PMRD, severe GvHD, and
CMV infection (P  .01 in all comparisons). Interestingly, the use
of steroids (and/or use of ABLC) was no longer a prognostic
parameter. The twice-weekly ABLC was well tolerated, with a
median increase in creatinine of 0.85 mg/dL.
This regimen of twice-weekly intravenous ABLC 4 mg/kg ap-
pears to compensate for the increased risk of IFI associated with
the use of steroids after allogeneic SCT. This prophylaxis resulted
in a low incidence of IFI in this analysis of 100 allograft recipients
and allowed the use of higher doses of steroids. To increase its
early efﬁcacy, the twice-weekly ABLC prophylaxis perhaps should
be started earlier than day 30.
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AMD3100 PLUS G-CSF RAPIDLY MOBILIZES HEMATOPOIETIC PRO-
GENITOR CELLS IN PATIENTS WITH NON-HODGKIN’S LYMPHOMA
(NHL) AND MULTIPLE MYELOMA (MM), INCLUDING THOSE TRADI-
TIONALLY CONSIDERED “POOR MOBILIZERS”
Stiff, P.1, Micallef, I.2, McCarthy, P.3, Magalhaes-Silverman, M.4,
Fromenberg, N.5, Weisdorf, D.6, Tricot, G.7, Territo, M.8,
Abodnour, R.9, Badel, K.10, Calandra, G.10 1Loyola University Medical
Center, Maywood, IL; 2Mayo Clinic, Rochester, MN; 3Roswell Park
Memorial Institute, Buffalo, NY; 4University of Iowa, Iowa City, IA;
5Thomas Jefferson University, Philadelphia, PA; 6University of Minne-
sota, Minneapolis, MN; 7University of Arkansas, Little Rock, AK;
8University of California Los Angeles, Los Angeles, CA; 9University of
Indiana, Indianapolis, IN; 10ArnorMed Inc., Langley, BC, Canada.
AMD3100 is a potent, selective antagonist of the CXCR4 che-
mokine receptor, blocking binding of its cognate ligand, stromal
cell–derived factor 1	. Administration leads to elevations in circu-
lating hematopoietic progenitor cells after 10–11 hours. Prelimi-
nary studies showed that more progenitor cells were mobilized into
the circulation when G-CSF and AMD 3100 were administered to
patients compared to G-CSF administration alone. To investigate
the degree of progenitor cell mobilization of AMD3100 and G-
CSF (10 g/kg/day), we treated unselected patients undergoing
autotransplantation for NHL and MM. G-CSF at 10 g/kg/day
for up to 9 days was administered SQ with AMD3100 at 240
g/kg/day SQ starting on the evening of day 4 of G-CSF (10–11
hours before planned daily aphereses) until 5 106 CD34/kg were
collected, or to a maximum of 5 days of a standard 3 blood volume
apheresis. Of 43 patients entered to date, 20 (6 myeloma, 14 NHL)
have been analyzed. Of these 20, 14 are considered to have been
heavily pretreated using standard deﬁnitions (10 cycles of chemo-
therapy, platinum-based salvage chemotherapy, and/or radiation
therapy to bone marrow sites).
Blood CD34 assays (cells/L) were performed before and after
each AMD 3100 dose and on each apheresis product. After the ﬁrst
dose of AMD3100 there were 2.6-fold and 3.0-fold increases in
CD34 cells/L in blood for the NHL and MM patients, respec-
tively. A median 2 aphereses were performed (range, 1–5); the
median total CD34 collected was 5.7  106/kg (range, 2.32–
14.58  106/kg). All patients had collections of  2.0  106 CD34
cells/kg, and in 14, the 5  106 CD34/kg cell dose goal was
collected, including 8 of 14 in the heavily pretreated group. In 6
patients, the 5  106 CD34/kg cell dose was collected in a single
apheresis. The median CD34/kg cell dose collected for the 14
heavily pretreated patients was 6.0  106/kg.
There were no serious adverse eeffects related to the use of
AMD3100. Transient diarrhea occurred in 44% shortly after the
injections of AMD3100, but only 3 patients required therapy.
Engraftment data for the ﬁrst 12 patients treated demonstrated
time to ANC  500/L and platelets  20,000/L of 9 days
(range, 8–10) and 12 days (range, 9–19), respectively.
The combination of AMD3100 and G-CSF appears to be effec-
tive in mobilizing large numbers of CD34 cells, and appears
superior to G-CSF alone in heavily pretreated patients, in whom it
appears to be a potentially less-toxic alternative to chemotherapy/
cytokine mobilization.
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INFLUENCE OF IMMUNOSUPPRESSIVE AGENTS ON MAGNESIUM (MG)
METABOLISM AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL
TRANSPLANTATION (HSCT): COMPARISON BETWEEN CYCLOSPORINE
A (CSA) AND TACROLIMUS
Aisa, Y., Mori, T., Shimizu, T., Yamazaki, R., Yamane, A., Adachi, A.,
Yokoyama, A., Nakazato, T., Ikeda, Y., Okamoto, S. Keio University
School of Medeicine, Tokyo, Japan.
Background: Calcineurin inhibitors, CSA and tacrolimus, are
universally used for the prophylaxis and treatement of graft-versus-
host disease (GVHD) after allogeneic HSCT. In addition to their
common adverse effects, including renal dysfunction, CSA and
tacrolimus cause hypomagnesemia due to the suppression of reab-
sorption of Mg from renal tubules. Because hypomagnesemia has
reportedly been associated with renal dysfunction and encephalop-
athy by CSA and tacrolimus, strict monitoring and management of
serum Mg level are necessary. We performed a prospective study
to evaluate Mg metabolism in recipients of allogeneic HSCT who
were receiving CSA or tacrolimus. Methods: Consecutive patients
undergoing allogeneic HSCT at Keio University Hospital between
January 2003 and July 2004 were enrolled. CSA (3 mg/kg/day) and
tacrolimus (0.03 mg/kg/day) were administered intravenously by
continuous infusion starting from day 1. The doses were ar-
ranged to maintain blood levels at 200–400 ng/mL for CSA and at
15–20 ng/mL for tacrolimus. Serum Mg and the total amount of
daily Mg excretion in urine were measured once before the admin-
istration of CSA or tacrolimus, and then once weekly after HSCT
for 4 weeks. Mg was supplemented intravenously by continuous
infusion to maintain the serum Mg level  1.5 mEq/L. Results:
Thirty-six patients were evaluable (12 in the CSA group and 24 in
the tacrolimus group). The serum Mg level began to decrease in
both groups from the ﬁrst week after HSCT, and was signiﬁcantly
lower in the tacrolimus group than in the CSA group from the ﬁrst
to the third weeks (P  .01). The total amount of daily Mg
excretion in urine and Mg supplementation began to increase in
both groups from the second week after HSCT, and they were
signiﬁcantly higher in the tacrolimus group than in the CSA group
(P  .01). Conclusions: Although both CSA and tacrolimus in-
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creased Mg excretion in urine and caused hypomagnesemia shortly
after initiating administration, the effect was more signiﬁcant with
tacrolimus than with CSA.
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POSACONAZOLE (POS) SALVAGE THERAPY ALLOWS SUCCESSFUL AL-
LOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN
PATIENTS WITH REFRACTORY INVASIVE MOLD INFECTIONS
Mullane, K.1, Toor, A.2, Rodriguez, T.2, Kalnicky, C.1, Klein, J.2,
Stiff, P.2 1Department of Internal Medicine, Section of Infectious Dis-
eases, and Bone Marrow Transplant Program, Loyola University Stritch
School of Medicine, Maywood, IL.
In patients with hematologic malignancies, invasive fungal infec-
tion (IFI) causes signiﬁcant morbidity and mortality, often posing
a contraindication to allogeneic HSCT. The overall rate of IFI
appears to be increasing even with use of antifungal prophylaxis.
Posaconazole (POS) is an extended-spectrum triazole with activity
against many fungal pathogens, including resistant molds. In this
open-label compassionate use salvage antifungal therapy study, 3
subjects with IFI caused by uncommon molds (Alternaria spp.
[rhinopulmonary], Paecilomyces lilacinus [pulmonary], and Zygomy-
cetes spp. [pulmonary and pericardial]) underwent allogeneic
HCST during POS therapy. Two patients had acute myelogenous
leukemia (AML), and 1 patient had multiple myeloma (MM).
Before starting POS therapy, all 3 patients had failed prophylaxis
with ﬂuconazole and salvage therapy with voriconazole (n  3),
caspofungin (n  2), and liposomal amphotericin B (n  3).
Median duration of antifungal therapy before starting POS was 2.5
months (range, 1.5–9 months). Two patients also required surgical
intervention for initial control. Median duration of POS therapy
before HSCT was 5 months (range, 1.5–6 months).
Treatment resulted in complete resolution of IFI in 1 patient and
improvement in 2 patients (based on follow-up CT scanning). The
patient with Zygomyces spp. had resolution of fungal pericarditis.
Subsequently, the 2 AML patients underwent conventional my-
eloablative conditioning, and the one MM patient received a re-
duced intensity regimen. Two patients also received antithymocyte
globulin. The stem cell sources were unrelated umbilical cord
blood, unrelated donor bone marrow, and related donor PBSC.
Graft-versus-host disease prophylaxis consisted of tacrolimus in 3
patients, methotrexate in 1 patient, and methylprednisolone in 1
patient.
Median time to myeloid engraftment was 13 days (range, 11–20
days). At 3 months posttransplantation, 2 patients are alive without
evidence of IFI. One patient died of recurrent AML 4 months after
transplantation without evidence of IFI. No toxicities were attrib-
utable to POS. Tacrolimus pharmacokinetics remained relatively
unchanged.
This preliminary report demonstrates that POS was effective in
treating invasive mold infections refractory to conventional anti-
fungal therapy, including amphotericin B, in these high-risk indi-
viduals allowing for allogeneic HSCT.
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THE EFFECTS OF HYPERGLYCEMIA ON HEMATOPOIETIC STEM CELL
TRANSPLANTATION
Mosallaei-Benjamin, M., Hamadani, M., Scoﬁeld, H., Holla, P.,
Selby, G. Oklahoma University Health Sciences Center, Oklahoma City,
OK.
Background: Studies of critically ill patients in intensive care
settings have correlated tight glucose control with a substantial
reduction in morbidity and mortality and length of hospital stay.
The impact of hyperglycemia in the hematopoietic stem cell trans-
plantation (HSCT) population has not been studied. The aim of
this study was to investigate the relationship between hyperglyce-
mia and morbidity and mortality in HSCT patients. Methods: A
retrospective chart review of 98 consecutive adult patients (age 
17 years) admitted between January 1, 2002 and October 31, 2003
to the University of Oklahoma Health Sciences Center BMTU
was performed. Patients who received myeloablation followed by
autologous (n  48) or allogeneic (n  47) HSCT were analyzed
in separate groups. Mean inpatient plasma glucose values were
used to stratify the patients into euglycemic (glucose  126 mg/
dL) and hyperglycemic (glucose  126 mg/dL) groups. The pri-
mary outcome was length of inpatient stay (LOS) from day 0 until
discharge. Secondary outcome measures were number of infections
indicated by positive blood cultures; evidence of venous line infec-
tion; urinary tract infection; Clostridium difﬁcile infection; radio-
graphic evidence of pneumonia; number of days on nonprophylac-
tic antibiotics; total number of simultaneous antibiotics used;
engraftment time (ANC  500); and number of febrile days (tem-
perature  101°F). A tertiary outcome measure was in-hospital
death. Results: LOS for the alloHSCT patients was signiﬁcantly
longer (P .02) in the hyperglycemic group (mean, 34.0 days) than
in the euglycemic group (mean, 24.7 days). The hyperglycemic
group had signiﬁcantly higher in-patient mortality (P  .0036),
number of infections (P .0015), and number of days on nonpro-
phylactic antibiotics (P  .0078) than the euglycemic group. LOS
was also signiﬁcantly (P  .01) longer for the hyperglycemic
autoHSCT patients (mean, 31.33 days) than for the euglycemic
patients (mean, 18.30 days). Hyperglycemic autoHSCT patients
also demonstrated a signiﬁcantly higher number of documented
infections (P  .028). Conclusions: This retrospective study in-
dicates that hyperglycemia is strongly associated with increased
mortality and morbidity and LOS in HSCT patients. Randomized
prospective studies are necessary to elucidate the beneﬁts that strict
glucose control may provide during hematopoietic stem cell trans-
plantation.
275
SHARED MEDICAL APPOINTMENTS (SMA): IMPLEMENTATION IN THE
BONE MARROW TRANSPLANTATION CLINIC
Meehan, K.R., Root, L., Kimtis, E.A., Patchett, L., Hill, J.M. Dart-
mouth-Hitchcock Medical Center, Lebanon, NH.
SMAs were implemented to provide patients increased time with
their care providers in an interactive setting, while sharing expe-
riences with other patients. These appointments allow care pro-
viders an opportunity to see more patients with similar needs in a
shorter period of time. SMAs have generally been limited to gen-
eral medicine or a few of its subspecialties, and have not been used
within the BMT population. Autologous stem cell recipients at our
center receive posttransplantation restaging evaluations at day 100,
every 6 months for 2 years, and then annually.
Eligible patients between 100 days and 2 years posttransplanta-
tion were contacted to participate in the SMA. Each patient’s
completed evaluation was forwarded to the BMT coordinator and
entered into the electronic templated note that was generated
before the visit. On the day of the SMA, brief exams and discussion
of conﬁdential issues were performed for each patient by a care
provider (2 MDs/1 NP) in a private ofﬁce, while the BMT coor-
dinator served as facilitator and prioritized patient questions raised
by the group.
On completion of the exams, the 3 care providers met with all of
the patients and answered questions in a group setting. Patients
were surveyed on completion of the SMA visit to evaluate the
format. Although 16 patients were eligible to participate in the
SMA, based on the timing of their workup and the SMA appoint-
ment, it was limited to 10 patients (7 with MM, 1 with AML, and
2 with NHL), to facilitate efﬁciency and ease of patient participa-
tion. Questions during the group meeting were general and appli-
cable to all patients, addressing such issues as hormone replace-
ment therapy, timing of vaccinations, and optimizing
posttransplantation quality of life. At completion of the 2.5-hour
visit, a survey was distributed, which indicated that patients pre-
ferred the SMA over a routine ofﬁce visit and will return again.
The BMT patient population is ideal for a tertiary care SMA.
These patients are highly motivated and issues discussed during the
group meeting were pertinent to all autologous transplantation
recipients, regardless of diagnosis. The SMA allows the patient to
spend a considerable amount of time with their care providers,
while providing the care providers an opportunity to discuss gen-
eral health questions pertinent to all transplantation patients in one
appointment. Our BMT program is expanding its SMA efforts by
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